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Abstract 
Malaria is a mosquito borne infectious disease caused by a protozoan of the genus Plasmodium. Humans are mainly 
infected by P. falciparum, P. vivax, P. ovale and P. malariae. Around 44% of world’s population is at risk from 
malaria. Malaria is one of the leading causes of morbidity and mortality in Ethiopia. The clinical features of malaria 
vary. The most characteristic symptom are fever, headache, lassitude, loss of appetite, muscle pain and chills, 
resulting in uncontrollable shivering with teeth chattering. Diagnosis of malaria is achieved by light microscopy, 
rapid diagnostic tests, polymerase chain reaction. Management of malaria includes general measures to be taken to 
save life of the person and prevention of recrudescence using drugs and other supportive measures. Parasite 
resistance to antimalarial medicines is a major threat to achieving malaria control and eventual elimination. The 
most important problem associated with the management of malaria are resistant to or is developing resistance to 
the most widely available, affordable and safest first line treatments. Prevention of malaria includes vector control 
to disrupt transmission from mosquito to human, prevention of infection and treatment after infection. V. 
amygdalina commonly called bitter leaf in English and ‘Girawa’ in Amharic. V. amygdalina has antimalarial 
properties and the aqueous extract of Vernonia amygdalina leaves exhibit antimalarial activity on P.falcifarum, 
P.vivax, P. ovale and P. malariae. Malaria is one of the life-threatening diseases. Moreover, Vernonia amygdalina 
can be used for the treatment of malaria in rural communities.  
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1. INTRODUCTION 
Malaria is a mosquito borne infections disease caused by a protozoan of the genus Plasmodium (Odeh and Usman, 
2014).Around 44% of world’s population is at risk from malaria. An estimated 3.2 billion people were at risk of 
being infected with malaria and developing disease in 2013. Of this, 1.2 billion people are at high risk (>1 case 
per 1000 population) of malaria. Over half of all the countries in the world are affected by malaria (RBMP, 2015).  
It is widespread in tropical Africa and Sub tropical regions including part of America, Asia and Africa (Odeh 
and Usman, 2014). In 2013, worldwide, there were an estimated 198 million cases of malaria. Most of these cases 
(82%) were in the WHO African Region, followed by the South-East Asia Region (12%) and the Eastern 
Mediterranean Region (5%). About 8% of estimated cases globally are due to P. vivax, although the proportion 
outside the African continent is 47% (WHO, 2014). 
Of the estimated 584,000 malaria deaths that occurred worldwide in 2013. 528,000 of these deaths, or 90%, 
were in the African Region, with 7% in the South-East Asia Region, and 2% were in Eastern Mediterranean Region. 
About 0.27 % people die every day from malaria; more than 0.24% of those people are in Africa. About 453,000 
malaria deaths were estimated to occur in children under 5 years of age, or 78% of the global total. Over 1,200 
children die every day from malaria, which is equivalent to 50 children dying every hour (RBMP, 2015). 
An estimated 437,000 of deaths occurred in children under 5 years of age in the WHO Africa Region, 
accounting for 83% of the total malaria deaths in the Africa Region, and 96% of total global under 5 malaria deaths. 
About 80% of malaria deaths in 2013 are estimated to occur in just 16 countries: Nigeria, Democratic Republic of 
the Congo, India, Angola, United Republic of Tanzania, Uganda, Ghana, Niger, Chad, Mozambique, Burkina Faso, 
Ethiopia, Côte d’Ivoire, Mali, Guinea, and Cameroon (RBMP, 2015). 
The parasites are spread to people through the bites of infected Anopheles mosquitoes, called "malaria 
vectors"(Singh, 2011).There are four parasite species that cause malaria in humans which are P.falciparum, 
P.vivax, P. malariae and P. ovale., P.falciparum and P. vivax are the most common species clinically but P. 
falciparum is the most deadly leading to many fatal complications including cerebral malaria (Singh, 2011). 
Malaria is one of the leading causes of morbidity and mortality in Ethiopia. An estimated 55.7 million people 
(68% of the population) are at risk for malaria and approximately 80% of the 736 districts in Ethiopia are 
considered “malarious”. Protective immunity in Ethiopian populations is relatively low due to unstable 
transmission and, unlike large parts of sub-Saharan Africa; all age groups are at risk of infection and disease. P. 
falciparum accounts for 65-75% of infections, while P. vivax accounts for 25-35%. P. ovale and P. malariae are 
rare (The Carter Center’s (TCC) Malaria Control Program (MCP), 2013). 
The World Health Organization (WHO) estimates that approximately 80% of the world’s inhabitants rely on 
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traditional or herbal medicines for their primary health care and plants have long formed the basis of sophisticated 
traditional medicine systems and purportedly provide excellent leads for new drug developments (Pravi, 2006; 
Akinjogunla et al., 2009). However, the increasing problems of multi-drug resistant (MDR) is of great concern to 
both the clinicians and pharmaceutical industries and this has made it significant to search for newer drugs that are 
highly effective, affordable, acceptable and available (Akinjogunla et al.. 2010).  
In developing countries where modern medicine is expensive, most of the indigenes people rely on indigenous 
plants for the treatment of various ailments (Qureshi et al., 2009). Traditional medicine has maintained its 
popularity in all regions of the developing world and its use is rapidly spreading in ten industrilized countries 
(Kassaye et al., 2006). 
Phytochemicals differ from phytonutrients in that they are not a necessity for normal metabolism and absence 
will not result in deficiency disease. Phytochemicals are not required for the functioning of the body, but they are 
of benefit on health and play an active role in the treatment of diseases (Audu et al., 2012). Therefore, the objective 
of this review paper is to insight the burden of malaria and antimalarial activity of V.amygdalina. 
 
2. LITERATURE REVIEW 
2.1. Global epidemiology of malaria 
Epidemiology of malaria is important for clear understanding of the distribution and transmission pattern of the 
disease. This is also relevant for the control of malaria at large. Several epidemiological studies have shown the 
degree, and intensity of transmission is varied within continents (Snow, 2005; Guerra et al., 2006). 
An estimated 3.2 billion people were at risk of being infected with malaria and developing disease in 2013. 
Of this, 1.2 billion people are at high risk (>1 case per 1000 population) of malaria. In 2013, there were 97 countries 
and territories with ongoing malaria transmission, and 6 countries in the prevention of reintroduction phase, 
making a total of 103 countries and territories, 196 internationally recognized countries affected by malaria. There 
were 198 million cases of malaria worldwide in 2013, with 82% of these cases occurring in Africa. In 2013,584,000 
people died from malaria worldwide, with 90% of these deaths occurring in Africa (WHO, 2014). 
Malaria occurs mostly in poor tropical and subtropical areas of the world. In many of the countries affected 
by malaria, it is a leading cause of illness and death. In areas with high transmission, the most vulnerable groups 
are young children, who have not developed immunity to malaria yet and pregnant women, whose immunity has 
been decreased due to pregnancy (CDC, 2015).  
P. vivax is regarded as the most cosmopolitan of the human malaria and the public health burden more 
significant that it causes severe morbidity and death. However, P. falciparum is the most serious intimidation to 
the world at a very scale. It causes more than 90% of death due to malaria. Four thousand years on, P. falciparum 
remains widespread in Africa. This may be due to optimal environmental conditions for Anopheline mosquito 
vectors, amid sustained poverty (Snow, 2015). The fluctuating pattern of malaria epidemiology throughout the 
world could be characteristics of complex interaction between environment, vector, the human host and the parasite 
species. 
 
2.2. Epidemiology of malaria in Ethiopia 
The 2011 Malaria Indicator Survey (MIS) shows that 1.3% of all age groups were positive for malaria using 
microscopy and 4.5% were positive for malaria using RDTs below 2,000 meters. P. falciparum constituted 77% 
of these infections (Malaria Operational Plan FY, 2014). According to the Federal Ministry of Health, malaria was 
the leading cause of outpatient visits and health facility admissions in 2010/2011, accounting for 15% of reported 
outpatient visits and nearly 15% of admissions. Malaria also was among the ten leading causes of inpatient deaths 
among children less than five years of age (Malaria Operational Plan Fiscal Year, 2014). 
About 75% of the geographic area of the country has significant malaria transmission risk (defined as areas 
<2,000 m), with about 68% of the country’s total population living in these areas. The FMOH estimates that there 
are about 12 million suspected malaria cases each year. The FMOH reported a total of 3,384,589 malaria cases 
from July 2011-June 2012, with1, 793, 832 (53.0%) of these laboratory confirmed, with 1,061,242 (59.2%) P. 
falciparum and 732,590 (40.8%) P.vivax. Ethiopia reported 936 malaria deaths in 2011, according to the 2012 
World Malaria Report (Malaria Operational Plan FY, 2014). 
 
2.3.  Etiology 
Malaria, the disease caused by protozoan parasites of the genus Plasmodium (Jennifer et al., 2005).All malaria is 
transmitted by female mosquitoes of the genus Anopheles. Humans are mainly infected by four species of 
Plasmodium: P. falciparum, P. vivax, P. ovale and P. malariae, although human infections with the monkey 
malaria parasite, P. knowlesi have also been reported recently in the forested regions of Southeast Asia (Kantele 
and Jokiranta,2011). The majority of all human malaria cases are caused byP. falciparum and P. vivax (Stainesl 
and Krishna, 2012). 
Anopheles gambiae the most aggressive among the more than 60 mosquito species that transmit malaria to 
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people in sub-Saharan Africa and bears partial responsibility for millions of human deaths per year (Vizioli et al., 
2000; Dunavan, 2005 and Legoff et al., 2006).P. falciparum and P. vivax are the two dominant parasite species 
with relative frequency of 60% and 40%, respectively in Ethiopia (Gezahegn, 2004).  
 ` 
2.4.  Life cycle 
The malaria parasite has a complex, multistage life cycle occurring within two living beings, the vector mosquitoes 
and the vertebrate hosts (Fakhreldin et al., 2003; Brian et al., 2008).The parasite passes through several stages of 
development such as the sporozoites, merozoites, trophozoites and gametocytes (sexual stages) and all these stages 
have their own unique shapes and structures and protein complements. The surface proteins and metabolic 
pathways keep changing during these different stages that help the parasite evade the immune clearance, while 
also creating problems for the development of drugs and vaccines (Fakhreldin et al., 2003). 
The sporozoite form of the parasite is inoculated into humans when bitten by an infected female Anopholes 
mosquito (Figure 1). The parasites go through several host cells by breaching their plasma membrane before 
infecting a final hepatocyte (Dunavan, 2005). Sporozoites rapidly enter the liver cells where they multiply to form 
thousands of merozoites. These then enter the blood stream where they invade red blood cells and multiply to form 
new merozoites. Infected red blood cells burst, releasing merozoites that infect new red blood cells. This is referred 
to as the asexual blood stage, the stage of the plasmodial life cycle that causes the clinical signs and symptoms of 
malaria. Some merozoites that invade the red blood cells develop into gametocytes, the sexual stages of the parasite. 
Gametocytes are ingested by the mosquito when it takes a blood meal. In the mosquito gut, the gametocytes 
develop into gametes and fuse to form a zygote. After fertilization, the zygote transforms into a motile ookinete, 
which penetrates the mosquito stomach wall and becomes an oocyst. The oocyst divides to produce sporozoites, 
which move into the salivary glands, from where another human can be infected when the mosquito takes a blood 
meal from (Stainesl and Krishna, 2012). 
           
Figure 1.Malarial merozoites in the peripheral blood.    Figure 2. Trophozoite form of the malarial parasite     
                                                                                         within peripheral erythrocytes (Thomas, 2018). 
 
 
Figure 3. A mature schizont within an erythrocyte (Thomas, 2018). 
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Figure 4. Plasmodium life cycle (Biamonte et al., 2013). 
 
2.5. Pathogenesis 
Proliferation of the parasite within the host’s erythrocyte takes place using hemoglobin as predominant source of 
nutrition. The malaria parasite digests hemoglobin within the digestive vacuole through the sequential metabolic 
processes involving multiple proteases (Tekwani and Walker, 2005).Malaria pathogenesis could be explained by 
Plasmodium falciparum erythrocyte membrane protein mediated sequestration of parasitized erythrocytes. This 
protein helps the parasite infected RBC adhere to blood elements including non infected erythrocytes, leukocytes, 
and wall of endothelial cells of microcirculation. These binding events enable parasitized erythrocytes to sequester 
and avoid clearance by the spleen and also contribute to disease by causing microvascular inflammation and 
obstruction (Rogerson et al., 2004; Fairhurst and Wellems, 2006). Cytoadherance of IRBCs on human dermal 
microvascular endothelial cells (HDMECs) is responsible for pathogenesis of malaria. IRBCs were observed to 
tether, roll, and adhere on resting HDMECs, rossets will be formed causing clogging of capillaries. IRBCs interact 
synergistically with multiple adhesion molecules on vascular endothelium (Bryan et al., 2000). 
Different factors participate in the neuro-pathogenesis of malaria. They seem to include abnormally high 
production of cell-derived cytokines such as tumor necrosis factor (TNF) and IFN- induced by infected 
erythrocytes. These cytokines may play an important role in causing certain pathological changes, by up-regulating 
the expression of cell surface markers like ICAM-1 and chondroitin sulfate A, thus leading to the sequestration of 
infected erythrocytes, leukocytes and monocytes in the cerebral capillaries. The pathogenesis of severe malaria 
therefore involves a cascading interaction between parasite and red cell membrane products, cytokines and 
endothelial receptors, leading to inflammation, activation of platelets, hemostasis, a procoagulant state, 
microcirculatory dysfunction and tissue hypoxia, resulting in various organ dysfunctions manifesting in severe 
malaria (Henri et al., 2006). 
 
2.6.  Clinical manifestations 
The clinical features of malaria vary. The most characteristic symptom is the occurrence of paroxysm which 
include fever with temperatures up to 40 - 41ºC at regular intervals –every 48 or 72 hours (tertian or quartan), 
alternating with good periods of no fever. This is preceded by headache, lassitude, loss of appetite, muscle pain 
and chills, resulting in uncontrollable shivering with teeth chattering. This is accompanied by thirst, nausea, 
vomiting. Severe and complicated malaria causing renal failure, hypoglycemia, anemia, pulmonary oedema, shock 
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and coma can have fatal consequences, leading to death (Singh, 2011). 
Nonimmune people, children and pregnant women who live in endemic regions are at highest risk of 
complications from malaria. Complications generally involve the central nervous, pulmonary, renal and 
hematopoietic systems. Hypoglycemia occurs because of parasite consumption of glucose and treatment with 
quinine. Acidosis is another common metabolic derangement. Severe anemia, acute renal failure, respiratory 
failure, intravascular hemolysis, coagulopathies, and shock may also develop (Kathryn et al., 2004).  
One of the most serious complications is cerebral malaria, manifested by altered level of consciousness, focal 
neurologic findings and seizures (Kathryn et al., 2004). Mortality is high (15% to 25%), and survivors may have 
residual neurologic deficits. Although semi-immune people and those living in endemic regions tend not to 
experience severe malaria, they may still experience complications from recurrent infections. In children, severe 
anemia is the most common complication of chronic malaria, with hematocrits approaching 15% (Kathryn et al., 
2004). The predominant manifestations of severe malaria in African children are cerebral malaria and severe 
anemia. P.falciparum slightly damages blood brain barrier (Gitau and Newton, 2005). Malaria is not only a direct 
cause of death but also contributes indirectly to death due to respiratory infections, diarrhea and malnutrition by 
impairing immunity (Kager, 2002). 
 
2.7.  Diagnosis 
2.7.1. Light microscopy 
In addition to providing a diagnosis with a high degree of sensitivity and specificity when performed well, 
microscopy allows quantification of malaria parasites and identification of the infecting species. It is considered 
to be the “field standard” against which the sensitivity and specificity of other methods must be assessed. A skilled 
microscopist is able to detect asexual parasites at densities of fewer than 10 per μl of blood, but under typical field 
conditions, the limit of sensitivity is approximately 100 parasites per μl (WHO, 2010). 
A high degree of suspicion and rapid diagnosisare essential to optimize outcome. Thick and thin peripheral 
blood smears, stained with Giemsa stain (or, alternatively, Wright’s or Field’s stains), remain the “gold standard” 
for routine clinical diagnosis. Malaria smears permit both species identification and quantification (expressed as a 
percentage of erythrocytes infected or as parasites per microlitre) of parasites but malaria should not be excluded 
until at least 3 negative blood smears have been obtained within 48 hours (Kathryn et al., 2004). 
2.7.2. Rapid diagnostic tests 
Rapid diagnostic tests are immunochromatographic tests that detect parasite-specific antigens in a finger-prick 
blood sample. Some tests detect only one species (P. falciparum), others detect one or more of the other species 
of human malaria parasites (P. vivax, P. malariae and P. ovale). They are available commercially in different 
formats, e.g. dipsticks, cassettes or cards. Cassettes and cards are easier to use in difficult conditions outside health 
facilities. Plasmodium lactate dehydrogenase (pLDH) or pan-specific aldolase. These antigens have different 
characteristics, which may affect suitability for use in different situations, and these should be taken into account 
when developing RDT policy (WHO, 2010). 
Current tests are based on the detection of histidine-rich protein 2 (HRP2), which are specific for P.falciparum, 
pan specific or species specific Plasmodium lactate dehydrogenase (pLDH) or pan-specific aldolase. These 
antigens have different characteristics, which may affect suitability for use in different situations, and these 2should 
be taken into account when developing RDT policy (WHO, 2010). 
The most practical of rapid malaria tests are the rapid antigen detection tests (RDTs), which detect parasite 
proteins in finger-prick blood samples. RDTs can identify only P. falciparum and P. vivax. Important shortcomings 
of RDTs include their inability toquantify parasitemia and suboptimal test performance with low-level parasitemia. 
Furthermore, some RDTs are unreliable as tests of cure because antigenemia may persist for prolonged periods 
even after treatment. But their simplicity may make them attractive and useful alternatives to blood smears, 
particularly in laboratories where expertise in reading blood films is lacking or in centers where malaria is 
infrequently encountered. Based on clinical studies involving both travelers to and residents of endemic areas, the 
overall sensitivity and specificity of RDTs for the detection of falciparum malaria are over 90%. However, 
sensitivity falls dramatically with low level parasitemia, and at present RDTs cannot be used alone to exclude 
malaria (Kathryn et al., 2004). 
2.7.3. Polymerase chain reaction (PCR) 
Techniques to detect parasite deoxyribonucleic acid (DNA), based on the polymerase chain reaction, are highly 
sensitive and very useful for detecting mixed infections, in particular at low parasite densities. They are also useful 
for studies on drug resistance and other specialized epidemiological investigations, but they are not generally 
available for large-scale field use in malaria endemic areas (WHO, 2010).However, most PCR assays do not have 
sufficiently rapid turnaround times to be clinically useful; therefore, PCR remains largely an investigational tool 
(Kathryn et al., 2004). 
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2.8. Treatment of malaria 
Management of malaria includes general measures to be taken to save life of the person and prevention of 
recrudescence using drugs and other supportive measures (Kathryn et al., 2004). Treatment of malaria depends on 
the infecting plasmodia species, the geographic area of acquisition (which affects the likelihood of drug resistance) 
and severity of infection (Kathryn et al., 2004; Sweetman, 2005). Falciparum malaria in nonimmune person is a 
medical emergency and requires rapid initiation of therapy (even in cases where the species cannot be immediately 
identified, the patient should be assumed to have drug resistant falciparum malaria until proven (Kathryn et al., 
2004). 
Once diagnosed and confirmed, malaria is treated with one or more drugs that have been licensed to be used 
as antimalarial agents. The currently available antimalarial drugs are grouped into four classes according to their 
chemical structure and biological activity: (i) quinoline based antimalarials which include quinine and its 
derivatives such as chloroquine, amodiaquine, premaquine, and mefloquine (ii) antifolate compounds 
(pyrimethamine , proguanil, dapsone, and sulfadoxine), (iii) artemisinin and derivatives (artemisinin, artesunate, 
artemether, arteether, dihydroartemisinin), and (iv) hydroxynapthoquinone (atovaquone) (Na-Bangchangb and 
Karbwang, 2009). 
The first-line treatment of uncomplicated P. falciparum malaria is artemether lumefantrine administered 2 
times a day for 3 days. For infants less than five kg of body weight and pregnant women, oral quinine 8mg/kg 
administered 3 times a day for 7 days is the first line treatment (for the treatment of malaria caused by P.vivax, 
P.malariaeor P.ovale, the drug of choice is chloroquine). Inmalaria-free areas and where compliance can be 
insured, in order to eliminate hypnozoite forms (relapsing stages) of P.vivax from the liver and to bring about 
radical cure, primaquine may be administered daily for 14 days starting after chloroquine treatment is completed. 
However, in malarious areas where there is a high risk of re-infection, and where the main purpose of treatment is 
to bring about clinical cure rather than radical cure, administration of primaquine is therefore, not recommended 
(Gezahegn , 2004).Second-line treatment is oral quinine if condition of the patient permits. Otherwise intravenous 
(IV) or intramuscular (IM) administration of quinine should be given (Gezahegn, 2004). In treatment of severe 
malaria, supportive therapy in reducing hyperpyrexia, controlling convulsions, maintaining fluid balance and 
correcting hypoglycaemia should be done (Sweetman, 2005).  
Along with these measures for management of other complications in severe malaria, loading dose of 
intramuscular or slow intravenous quinine should be used. Maintenance dose should be followed twelve hours 
after the start of the loading dose until the patient can take oral medication. Artemether-lumefantrine or oral quinine 
could be administered if intramuscular or slow intravenous quinineis not available (Gezahegn, 2004). Radical 
treatment and curative treatment comprise main aspects of treatment. Various pharmacological options available 
for this purpose are chloroquine, mefloquine, quinine, primaquine, pyremethamine, artemisinin derivatives like 
artesunate, artemether, arteether and amino alcohols like lumefantrine and halofantrine along with tetracycline, 
doxycyclines and sulfadoxime etc (Bahekar and Kale , 2013).  
 
2.9.  Antimalarial resistance 
Parasite resistance to antimalarial medicines is a major threat to achieving malaria control and eventual elimination. 
Antimalarial resistance in P. Falciparum parasites results in an enormous public health and economic burden 
(Stainesl and Krishna, 2012). Antimalarial resistance spreads when parasites are exposed to the selective window 
of drug concentrations that are sufficient to kill sensitive but not resistant parasites. Drugs with longer terminal 
elimination half-lives have the advantage of providing a longer post-treatment prophylactic effect, which appears 
to be important for their action in intermittent preventive therapy (IPT) in high-risk groups such as pregnant women, 
infants and young children. However, these longacting antimalarials have the disadvantage of residual 
concentrations inhibiting sensitive parasites far longer than resistant parasites, thus fuelling the spread of resistance. 
The window of selection is prolonged with an increase in resistance or in the terminal elimination half-life (unless 
these terminal concentration are too low even to kill sensitive parasites) (Stainesl and Krishna, 2012). Antimalarial 
resistance spreads because gametocyte carriage and infectivity to mosquitoes is consistently higher in patients 
infected with drug-resistant compared with drug-sensitive parasites. An increase in gametocyte numbers has been 
identified as the first indication that an antimalarial is beginning to fail and emphasizes the need for the treatment 
policy implemented to include drugs that will kill the sexual stages. Combining antimalarials with differing modes 
of action is expected to reduce the probability of a resistant (mutant) parasite surviving treatment. Despite their 
mismatched elimination half-lives, ACTs are preferred to other combination therapies given their potential to 
reduce malaria transmission – due to their rapid clearance of asexual parasites together with their partial 
gametocidal activity (Stainesl and Krishna, 2012). Some of the selected antimalarial drugs and its mechanisms of 
resistance described as depicted in table 1.  
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Table 1. Selected antimalarial drugs and its mechanisms of resistance. 
Drug  Mechanism of Resistance 
Chloroquine Decreased intraparasite accumulation of chloroquine. 
Probably predominantly mediated by mutations in PfCRT, a 
transmembrane protein in the parasite phagolysosome, 
resulting in increased efflux of chloroquine from the lysosome 
(Warhurst, 2001)). Mutations in multidrug resistance (MDR) 
P-glycoprotein pumps (Pgh) encoded by Pfmdr1and 
Pfmdr2may also contribute Warhurst, 2001). 
Mefloquine,  halofantrine, quinine Mefloquine and halofantrine resistance may be related to 
amplification of Pfmdr1, increased expression of Pgh1, 
mutations in pfcrt, and increased efflux of drug (Milhous and  
Kyle.,1998). The details of quinine resistance have not been 
established, although quinine and mefloquine resistance often 
correlate (White, 1998). 
Cycloguanil, chlorcycloguanil, pyrimethamine Resistance mediated through point mutations in dihydrofolate 
Reductase (dhfr) and dihydrofolate Synthase (dhps) genes, 
although more efficient use of available folate may also 
contribute (White, 1998). 
Sulfonamides and Sulfones   
 (sulfadoxine, dapsone)  
Atovaquone Point mutations in mitochondrially encoded cytochrome b 
gene (Srivastava, 1999). 
2.9.1. Determinants of drug resistance and treatment failure 
Clinically relevant resistance to antimalarial drugs emerges primarily through increasesin the prevalence of 
resistance-conferring gene mutations in an environment of selective drug pressure. Parasites survive the presence 
of drugs through mutation. Mutations occur at random because of replication errors. Many of those mutations are 
lethal and the parasite will die. Occasionally, a mutation will confer on a parasite a survival advantage when a 
given drug is present. This parasite, provided it is not cleared by the host’s immune system, will proliferate and its 
progeny carry that mutation. Additional survival advantage could be gained by further mutations. This process 
generates populations of parasites with different abilities to survive a drug. Over time, the parasite populations 
with the greatest survival advantage will predominate (Rosenthal, 2001).  
The range of naturally occurring drug susceptibilities within a parasite population is a function of the size of 
the circulating population of parasites (the “biomass” or “parasite burden”); a larger parasite biomass increases the 
chances for parasite mutation, broadening the distribution of parasite susceptibilities within that population. If a 
mutation does not compromise other biologic functions or confers a net survival advantage in the presence of a 
given drug, the possibility exists, provided the parasite carrying that mutation escapes the host’s immune defenses, 
that the parasites with the mutation will be selected for and transmitted (Rosenthal, 2001).   
2.9.2. Factors involved in the generation of drug resistance 
2.9.2.1.  Pharmaco-biological factors 
Pharmacological factors that influence the rate of development of resistance include the drug’s pharmacokinetic 
and pharmacodynamic characteristics, as well as the drug’s intrinsic propensity to generate resistance. Drugs with 
a long residence time in the organism and a slow rate of reduction of the parasite “biomass” are more vulnerable 
to resistance. Equally vulnerable are drugs against which resistance develops through single-point mutations in the 
target molecule (also referred to as single nucleotide polymorphism (SNP), such as the antifolates and atovaquone. 
By contrast,the quinolines (chloroquine [CQ], quinine) have enjoyed a longer therapeutic life-span because 
resistance to these drugs is apparently multigenic-the greater the number of genes involved, the slower resistance 
will evolve(Rosenthal, 2001).   
2.9.2.2. Epidemiological factors 
One determinant of resistance development is the self-fertilization that occursbetween male and female 
gametocytes when they are picked up by a mosquito during ablood meal. Such reassortment determines the 
mutations that are carried by the ensuinggeneration of parasites that are transmitted to the next individual(s). In 
this process, theintensity of transmission plays a critical, yet undetermined, role, which is principallyrelated to the 
number of parasite clones carried by each individual (Rosenthal, 2001).   
The intensity of transmission may influence resistance indirectly, via mechanisms such as immunity and drug 
use. Intense, continuous transmission favors the early acquisition of immunity, at the cost of increased mortality. 
This should, in theory, confine use of antimalarial drugs-thus limiting the ensuing selection pressure on parasites-
to the younger age groups (primarily, children under 5 yr). In practice, this is not always true, and antimalarials 
are often used by all age groups to treat fever. Additionally,high rates of transmission increase the probability that 
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parasites will be exposed to subtherapeutic drug levels, especially drugs with long half-lives. People living in areas 
where transmission occurs at lower rates have fewer malaria attacks but, because the level of acquired immunity 
is far less, remain at greater risk of severe malarial illness for their entire lives(Rosenthal, 2001).   
2.9.2.3. Operational and behavioral factors 
The way that drugs are used by both health care providers and patients plays an important role in determining 
drugs’ useful life-spans. Of particular concern are the manner in which drug policies are formulated and 
implemented and the extent to which official policy can influence practice: specifically, whether drugs are 
available only with a physician’s prescription or whether they are readily available on the open market; whether 
antimalarials are prescribed only to patients with a proven malaria infection or whether they are prescribed on the 
basis of a clinical suspicion alone; the extent to which providers (whether formal or informal) and users of 
antimalarial drugs adhere to official recommendations; and whether the cost or complexity of the recommended 
regimen might encourage incomplete dosing(Rosenthal, 2001).   
The way that people use antimalarial drugs greatly affects the degree of selective drug pressure; many 
behaviors result in exposure of parasites to inadequate or sub therapeutic drug levels, which, in turn, facilitate 
development of resistance. One example is the interplay between people’s perceptions of illness and the likelihood 
of completing a full treatment course. Because people from many cultures perceive illness in terms of symptoms 
rather than causes, community perceptions of illness and their beliefs and practices related to treating those 
symptoms can differ greatly from Western biomedical definitions of malaria-related illness. Once the symptoms 
are gone, the illness is perceived to be gone as well. Patients’ treating themselves with drugs that produce rapid 
relief of symptoms, such as artemisinin compounds apparently do, may be more likely to stop before the complete 
regimen is completed, thereby exposing parasites to a sub therapeutic dose (Rosenthal, 2001).  
2.9.3. Clinical consequences of drug resistance and treatment failure 
2.9.3.1. Reduced treatment efficacy 
The most obvious consequence of antimalarial drug resistance is a failure of the drug to produce a rapid and 
complete cure. This consequence can be manifested in a variety of ways (Rosenthal, 2001).  
2.9.3.2. Delayed initial therapeutic response 
This is considered by many to be the first sign of resistance. The rate of parasite and fever reduction is influenced 
not only by parasite susceptibility but also by host factors and the drug’s pharamacokinetic and pharmacodynamic 
characteristics (Rosenthal, 2001).  
2.9.3.3.  Parasitologic recrudescence and return of clinical symptoms 
In some settings, recrudescent infections tend to be clinically silent. Nonetheless, the return of clinical symptoms 
associated with recrudescent parasitemia is probably the most common clinical consequence of failed treatment 
(Rosenthal, 2001).  
2.9.4. Public health consequences of drug resistance 
2.9.4.1. Increases in malaria transmission 
At the simplest level, poor therapeutic efficacy fails to remove parasites from infected individuals, thereby 
maintaining a larger population of parasitemic individuals in a given area and maintaining a larger biomass of 
parasites contributing to malaria transmission. Drug resistance is also more directly associated with a potential for 
increased transmission by enhancing gametocyte carriage. This can be a result of longer parasite clearance times, 
which are associated with increase gametocyte carriage, or increased frequency of recrudescent infections, which 
are twice as likely to carry gametocytes compared with primary infections (Rosenthal, 2001).  
2.9.4.2. Frequency of severe illness 
On an individual basis, the primary concern with failed malaria treatment is progression to severe, potentially life-
threatening or fatal illness. Crude estimates of the number of clinical attacks of malaria among African children 
range from 1 to 5 per year; of these, an estimated 2% of these attacks are severe. Malaria morbidity and mortality 
has nonetheless increased because of the number of severe malaria cases that develop because of ineffective first-
line treatment (Rosenthal, 2001).  
2.9.4.3. Mortality rates 
Estimates of the impact of effective treatment on the mortality rate of malaria range from a 50-fold decrease in 
probability of mortality among uncomplicated malaria cases (from about 5% to 0.1%) to a 5-fold decrease in 
probability of mortality among patients with severe illness (from nearly 100% to 15–20%) (58). As treatment fails, 
the overall case-fatality rate undoubtedly rises (Rosenthal, 2001). 
 
2.10. Immunity against malaria 
During its complex, multi-stage life cycle, the malaria parasite not only expresses a great variety of proteins at 
different stages, but these proteins also keep changing often. As a result, a natural infection with malaria parasites 
leads to only a partial and short lived immunity that is unable to protect the individual against a new infection 
(Doolan et al., 2009). 
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2.10.1. Natural or innate immunity 
Natural or innate immunity to malaria is an inherent refractoriness of the host that prevents the establishment of 
the infection or an immediate inhibitory response against the introduction of the parasite. The innate immunity is 
naturally present in the host and is not dependent on any previous infection. Alterations in the structure of 
hemoglobin or in certain enzymes have been found to confer protection against either the infection or its severe 
manifestations and these traits are often found in areas of high malaria transmission. Duffy negativity in red cells 
protects against P. vivax infection. Certain thalassemias (50% reduction in infection), homozygte hemoglobin C 
(90% reduction), hemoglobin E, and ovalocytosis carrier status have been reportedto confer protection against P. 
falciparum or P. vivax. Glucose 6 phosphate dehydrogenase deficiency (50% protection) and sickle cell 
hemoglobin (90% protection) confer protection against severe malaria and related mortality (Doolan et al., 2009). 
2.10.2. Acquired or adaptive immunity 
Acquired or adaptive immunity against malaria develops after infection and its protective efficacy varies 
depending on the characteristics of the host, place of stay, number of infections suffered etc. It has been graded as 
anti-disease immunity (that protects against clinical disease), anti-parasite immunity (protects against high 
parasitemia), and sterilizing immunity (protects against new infections by maintaining a low-grade, asymptomatic 
parasitemia; also called premunition), with a considerable overlap between these. Following infection with malaria 
parasites, a nonimmune individual commonly develops an acute clinical illness with very low levels of parasitemia 
and the infection may progress to severe disease and death. After a couple of more infections, anti-disease 
immunity develops and causes suppression of clinical symptoms even in the presence of heavy parasitemia and 
also reduces the risk of severe disease. Frequent and multiple infection slowly lead to the development of anti-
parasite immunity that results in very low or undetectable parasitemia. Sterilizing immunity, though never fully 
achieved, results in a high degree of immune responsiveness, low levels of parasitemia, and an asymptomatic 
carrier status. Premunition suggests an immunity mediated directly by the presence of the parasites themselves and 
not as much the result of previous infections (Doolan et al., 2009). 
The acquisition of immunity against malaria is, therefore, very slow and not very effective and remains 
species specific and strain specific. People living in unstable endemic areas tend to acquire only partial immunity 
(Doolan et al., 2009). The acquired anti malaria immunity does not last long. In the absence of re-infection for 
about 6 months or 1 year, as may happen when the person leaves the malarious area, the acquired immunity turns 
ineffective and the individual becomes vulnerable to the full impact of a malarial infection once again (Doolan et 
al., 2009).  
 
2.11. Prevention of malaria 
The current approach to manage the disease includes vector control to disrupt transmission from mosquito to 
human, prevention of infection and treatment after infection (Tripathi et al., 2005). Prevention of the disease 
includes vector control to disrupt transmission from mosquito to human which can be achieved using insecticide 
treated nets and genetically engineered mosquitoes (Tripathi et al., 2005;). But nowadays high insecticide 
resistance resulting from insensitive acetyl cholinesterase (AchE) has emerged in mosquitoes (Weill et al., 2004). 
2.11.1. Avoiding the bite 
The best way to avoid getting bitten by a mosquito is to avoid mosquitoes entirely. Mosquitoes are most active at 
dusk and dawn, so avoiding outdoor activity at those times limits exposure to the insect. Wearing protective 
clothing, particularly light-colored clothing that radiates infrared light much less than darker clothes, helps to avoid 
a mosquito’s bite (Marcus, 2009). 
2.11.2. Eliminating breeding grounds 
Other means of avoiding mosquitoes involve limiting their opportunities to breed and find you when you are 
vulnerable. Mosquitoes can also breed in swimming pools, birdbaths, fountains, animal watering troughs, roof 
gutters, and even in carelessly discarded cans and beverage containers. Denying mosquito’s access to such objects, 
by keeping them dry whenever possible, or removing litter where water can accumulate, limits the opportunities 
of mosquitoes to reproduce. In cases where water must stand, as in swimming pools, chemicals such as chlorine 
can be added to the water to kill mosquito larvae. In some cases, mosquito fish (Gambusia affinis) can be 
introduced into water (Marcus, 2009). 
2.11.3. Using protective barriers 
Protective barriers are anything that physically blocks a mosquito’s access to its prey. By reducing the number of 
mosquitoes that enter a house, window screens do reduce the risk of malaria to the people inside it. Another 
protective barrier that can work quite effectively is bed netting. Bed netting can be even more effective when 
impregnated with insect repellents or, better still, insecticide. In Ethiopia, in particular, the Carter Center has been 
providing people with bed netting impregnated with pyrethrum, a natural insecticide extracted from 
chrysanthemums (Marcus, 2009). 
2.11.4. Using repellents 
Certain areas such as deep woods or swamps have mosquito populations that may be so dense and/or hungry that 
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the mosquitos may be active at all hours, including in bright sunlight. Moreover, there are times when people have 
to be out at dusk or dawn. In such cases, chemical mosquito’s repellents can be used to prevent bites. The repellent 
makes the person wearing it seem too unappealing to bite (Marcus, 2009). 
2.11.5. Using chemoprophylaxis 
Antimalarial drugs which act at different stages of malaria parasite can be used for prophylaxis or treatment of 
malaria. They are classified as blood schizonticides, tissue schizonticides and gametocides (Michel et al., 
2002).Mass chemoprophylaxis cannot be done for all people in malaria endemic areas. However, it can be done 
for those at high risk of malaria like children and pregnant women, particularly primigravidae, though costly 
(Kathryn et al., 2004 and Sweetman, 2005). Special risk group exposed to malaria such as long term travelers, 
children, pregnant women, aircrew, migrants to visit malarious areas need prophylaxis (Shanks and Edestein, 
2005). 
Malaria related morbidity and mortality can be reduced in children less than 5 years of age by either 
intermittent or continuous chemoprophylaxis. Chemoprophylaxis during pregnancy increases infant birth weight 
and survival, although this effect is largely limited to primi gravidae. Travelers to malaria endemic areas are also 
recommended to take drugs to prevent malaria (Kathryn et al., 2004). Chemoprophylaxis should be started 2 weeks 
before departure and continued for four weeks after return from the malarious area. For non-immune travelers 
visiting malarious areas for a period of 2- 3 months, weekly mefloquine administered at 5 mg/kg is the 
recommended drug for chemoprophylaxis (Michel et al, 2002; Fairhurst and Wellems, 2006). 
 
3. Vernonia amygdalina 
Medicinal plants are various plants thought by some to have medicinal properties, but few plants or their 
phytochemical constituents have been proven by rigorous science or approved by regulatory agencies such as the 
United States Food and Drug Administration or European Food Safety Authority to have medicinal effects. A 
medicinal plant is any plant which, in one or more of its organs, contains substances that can be used for the 
therapeutic purposes or which are precursors for the synthesis of useful drugs (Audu et al., 2012). 
 
3.1.  Brief description 
V. amygdalina Del, commonly called bitter leaf in English and ‘Girawa’ in Amharic, is a perennial shrub of 2-5m 
in height that grows throughout tropical Africa. It has a rough bark with dense black straits, and elliptic leaves that 
are about 6 mm in length. The leaves are green and have a characteristic odor and bitter taste (Ijeh and Ejike, 2011). 
 
Figure 5. Picture of V. amygdalina leaf 
3.1.1. Scientific classification of Vernonia amygdalina 
Kingdom: Plantae  
Division: Angiosperms 
Order: Asterales 
Family: Asteraceae 
Genus: Vernonia 
Species: V. amygdalina 
Botanical Name: Vernonia amygdalina (Audu et al., 2012). 
3.1.2. Habitat and distribution 
Vernonia amygdalina (Del.) commonly called bitter leaf is the most widely cultivated species of the genus 
Vernonia which has about 1,000 species of shrubs (Munaya, 2013).It is grown in many countries, in savannah 
zones and cultivated. Although most popularly used for food, it has also, been traditionally used for its medicinal 
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properties. True to its name, bitter leaf is bitter to taste but surprisingly delicious in meals (Abosi and Raseroka, 
2003). It is found in wide range of bush land, wood land and forest habitat 1200-3000 mean above sea level (masl) 
in Bale, Wollo, Gondar, Gojam, Wellega, Shewa, Illubabor, Kefa, Hararge and Gamo Gofa floristic regions 
(Mesfin, 2004).  
3.1.3. Medicinal uses 
V. amygdalina Del. is probably the most used medicinal plant in the genus Vernonia (Erasto et al., 2006). The 
observation that an apparently sick wild chimpanzee chewed V. amygdalina Del. and seemed to return to normal 
activity after a while. Traditional medicine, practitioners use the plant as an antihelminth, anti-malarial, and as a 
laxative. Others use it as a digestive tonic, appetizer, febrifuge and for the topical treatment of wounds (Ijeh and 
Ejike,2011). 
V. amygdalina Del. has antibacterial, antiplasmodial/antimalarial, amoebicidal, antifungal, antileishmanial, 
antischistosomial, wound management, venereal disease management, anticancer/tumor, antioxidant, 
hypoglycemic/antidiabetic, hepatoprotection, nephroprotection, serum lipid modulation, gastric secretion, 
analgesic, antifertility and insecticidal properties (Ijeh and Ejike,2011). Its Leaf decoction is used to treat fever, 
malaria, diarrhea, dysentery, hepatitis and cough as a laxative and as fertility inducer. They are also used as 
medicine for scabies, headache, and stomach ache. traditional root extract are also use as treatment against malaria 
and gastrointestinal disorders. It is also useful as a control agent against disease in plant. The ash from burnt 
branches is used to control seed-borne fungi (Aspergillus, Fusarium and Penicillium spp) (Odeh and Usman, 2014).  
In Ethiopia Vernonia amygdalina is used for the treatment of internal worms, stomach ache, malaria and 
‘mich’ in Amaro Woreda (Fissehaet al., 2014), malaria, ascarisis and around in Hawassa city, southern Ethiopia 
(Reta,2013), flariasis and ascariasis (Tolosa, 2007). Elsewhere in Ethiopia used against menstruation pain, as 
purgative and vermifuge, in wound dressing and against urinary inflammations and against malaria, evil eye and 
diarrhoea (Debela, 2001). 
3.1.4. Antimalarial properties of V. amygdalina Del. 
Malaria is said to be responsible for approximately one million infant deaths every year in sub-Saharan Africa 
(Abosi and Raseroka, 2003). What is worrisome is that the parasite is becoming resistant to a number of the current 
drugs for malaria treatment available in the market. Abosi and Raseroka (2003) reported that the ethanolic extract 
of the leaves and root-bark of Vernonia amygdalina suppressed parasitemia (induced by inoculation with 
Plasmodium berghei) in mice by 67% and 54%, respectively in four days. The aqueous extract of the leaves of the 
plant has also been shown to reduce the load of P. berghei in mice by 73% when given intraperitoneally for 4 days 
(Njan et al., 2008). It is thought that the flavonoids, saponins and alkaloids (Sayed et al., 1987) and sesquiterpene 
and steroidal constituents (Phillipson et al., 1993) are responsible for the antiplasmodial properties of VA (Ijeh 
and Ejike, 2011). 
The aqueous extract of Vernonia amygdalina leaves exhibit antimalarial activity on Plasmodium falcifarum, 
Plasmodium vivax, Plasmodium ovale and Plasmodium malariae even though some of these strains are resistant 
to conventional antimalarial drugs, they were susceptible to this plant especially at higher concentration (Odeh and 
Usman , 2014). So, in traditional practices ,Vernonia amygdalina (bitter leaf) is used in the management of 
parasitic infection most importantly, Malaria fever which is the most rampant of the parasitic infection(Odeh and 
Usman , 2014). 
The ethanol, petroleum ether, dichloromethane, ethyl acetate, acetone-water and isoamyl alcohol extracts of 
V. amygdalina, showed antimalarial activity against Plasmodium falciparum (Dd2) in vitro (Masaba, 2000; Tona 
et al., 2004). The root extract of V. amygdalina displayed mild activity against chloroquine-sensitive P. falciparum 
with IC50 of 19 µg/ml but no activity against the chloroquine-resistant strain. 
This antimalarial effect of V. amygdalina is contributed by its active compounds, or more specifically 
sesquiterpene lactones such as vernolepin, vernolin, vernolide, vernodalin and hydroxyl vernodalin which 
exhibited antiplasmodial activity of IC50 value lower than4 µg/ml (Tona et al., 2004). Besides, Masaba 
(2000)discovered that acetone-water extract from V.amygdalina leaves showed lower IC50 value (25.5 
µg/mlagainst P. falciparum than water extract (76.7 µg/ml) after 48h. 
Furthermore, Iwalokun (2008) showed that this aqueous leaves extract (62.5, 125 mg/kg) was able to work 
synergistically with chloroquine (5 and 30 mg/kg) against both chloroquine-sensitive and resistant P.berghei to 
shorten the parasite clearance time, prolong the recrudescent times and improve curing rate. The study has also 
suggested that administration of V.amygdalina ethanol extract 1 h prior to chloroquine intake can avoid the 
reduction in chloroquine bioavailability (Igboasoiyia et al., 2008). 
3.1.5. Phytochemical constituents of V. amygdalina Del. 
A wide array of phytochemicals (including anti-nutritional factors) has been shown to be present in V. amygdalina. 
A summary of the phytochemicals present in V. amygdalina. Stigmastane-type saponins such as vernoniosides A1, 
A2, A3 (Jisaka et al., 1992), A4, B2, B3 (Jisaka et al., 1993a), C, D and E (Ohigashi, 1994) have been shown to 
be present in the leaves. The A-series saponins have been shown to be responsible for the bitter taste of V. 
amygdalina. Other steroidal saponins have been identified in the plant. Sesquiterpene lactones are another class of 
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phytochemicals found abundantly in the leaves of V. amygdalina. Some of the identified Sesquiterpene lactones 
are vernolide, vernodalol,vernolepin, vernodalin and hydroxyvernolide flavonoids luteolin, luteolin 7-О-β-
glucoroniside and luteolin 7-О-β-glucoside are found in the leaves of V. amygdalina. Other researchers have 
confirmed the presence of flavonoids in the plant. Other phytochemicals present in the leaves of V. amygdalina 
are terpenes, coumarins, phenolic acids, lignans, xanthones and anthraquinones (Ijeh and Ejike,2011). 
3.1.6. Toxicity and Safety of V. amygdalina 
Toxicology studies had been carried out via both in vitro and in vivo systems on various subjects to confirm the 
toxicity of V. amygdalina. As indicated in Table 2, V. amygdalina only induced mild toxic effect when 
administrated at very high concentration. More importantly, safe consumption dosage needs to be identified for 
women at different stages or vitality of pregnancy, to avoid abortion since it may induce uterine contraction (Yeap 
et al., 2010). 
Table 2. In vitro and in vivo toxicity of V. amygdalina. 
Animal  Extract Route  LD50 
(mg/kgb.w.) 
Remark 
     
Mice  Aqueous (500-2000mg/kg/day for 14consecutive 
days) 
Oral - No signs of toxicity or adverse toxicological effects at all doses 
except for  
decrease of red blood cell count and dose dependent increase of 
serum bilirubin  
(Njan et al., 2008). 
 
 25% of V. amygdalina dry powder (or equivalent 
amount of ethanol extract or crude/purified 
saponins) for 2 weeks 
Oral - Reduction of body and liver weights and increase of urinary and 
fecal output associated with stomach and small intestines 
enlargement (Igile et al., 1995a). 
  
Aqueous (62.5 and 125 mg/kg) 
 
 
 
 
 
Aqueous (87.53 to 92.57g/kg) 
 
 
Aqueous (50 and 100 mg/kg) 
 
 
 
Ethanol (up to 1000 mg/kg for 1 month) 
 
 
 
Cold water (for 24 h)  
 
Oral  
 
 
 
 
 
Oral 
 
 
IP 
 
 
 
Oral 
 
 
 
IP 
 
 
 
 
 
 
 
- 
 
 
- 
 
 
 
- 
 
 
500 to  
1265.22 
 
Serum glutamate oxaloacetate transaminase (sGOT), serum 
glutamate pyruvate tansaminase (sGPT) and lactate dehydrogenase 
(LDH) level rose around 6-33%. Increase of serum enzyme markers 
level was more severe when it was consumed with antimalarial drug 
chloroquine (Iwalokun, 2008). 
 
No change in organ damage, blood count and liver enzyme 
profile (AST and ALT) (Amoleet al., 2006). 
 
No change of liver function diagnostic enzymes level (total 
bilirubin, conjugated bilirubin, unconjugated bilirubin,alanine 
aminotransferase, aspartate aminotransferase and alkaline 
phoosphatase) (Ojiako and Nwanjo, 2006). 
No change in liver (ALT, AST, ALP, total and conjugated 
bilirubin) and kidney (creatinine) enzymes marker level 
(Ekpo et al., 2007). 
 
(Nwanjo, 2005; Ojiako and Nwanjo, 2006). 
     
Rat Aqueous (250 and 500 mg/kg/day for 5 consecutive 
days) 
Oral  - Reduction of spermatozoa mobility and viability in dosage 
dependent mode. Hypoplasia of the seminiferous tubules was also 
observed in the treated rats. (Oyeyemi et al.,2008). 
 
 
 
 
 
 
Aqueous extract of V.amygdalina, Ocimum 
gratissimum and Gongronema latifolia (ratio 
1:1:1 at 16 g/kg b.w. (p.o) and 2.5 g/kg b.w. (i.p.) 
 
Oral,IP 
 
- 
 
No significant change in general behaviour (Iroanya et al., 2010). 
 Methanol (50, 100 and 200 mg/kg) Oral   Diarrhea and abortion (Awe et al., 1999) due to cathartic effect 
through weak contractile effect on smooth muscle. 
 
 
 
 
Rabbit 
 
 
 
 
 
Guinea pig 
 
 
 
Murine 
macrophages 
J774 
 
Allium cepa 
root tip 
 
 
Powder in standard food (25-75%) 
 
Aqueous 
 
Aqueous (0.3 mg/ml) 
 
 
 
Aqueous (10 and 100 mg/kg) 
 
 
 
 
Lipophilic extract 
 
Cold water extract  
 
 
Oral 
 
IP 
 
injection 
 
 
oral  
 
 
 
 
In vitro  
 
 
In vitro 
 
 
 
 
1112 
 
 
 
 
 
 
 
 
 
 
IC50 6.48 
µg/ml 
1% after 8h of 
incubation 
 
Skin of the rat turned lighter without alteration of tissues architecture 
and cellular morphology. (Ibrahim et al., 2001).  
 
(Akah and Okafor, 2006) 
 
Increase of uterine, intestine and jejunum contractionwhich sustained 
for 30 minutes with elevatedconcentrations used (Caiment-Leblond, 
1957;Kamatenesi-Mugisha et al., 2005). 
Increase of uterine and mammary gland contraction amplitudes and 
thus increase milk production and help in infant’s delivery (Ijeh et 
al., 2008). This supports the traditional use of V. amygdalina as an 
oxytocic plant in assistance of child birth traditionally. 
(Ganfon et al., 2008) 
 
 
Induced mitodepressive effect. Higher concentration of the extract or 
extensive incubation caused sticky effect on chromosomes during 
cell division and protein denaturation lead to nuclear disintegration 
and cell death. Presence of sesquiterpene lactones were suggested as 
the major contributors to this effect (Ene-Obong and Amadi, 1987). 
     
Generally, V. amgydalina is safe to consume and is good for health unless it is consumed in very large 
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quantities and the potential danger of taking this plant is much lower than that of other common vegetables (Ojiako 
and Nwanjo, 2006). V. amygdalina may cause adverse effect over the male reproductive system without controlled 
regimen (Yeap et al., 2010). 
 
4. CONCLUSION  
Malaria is one of the life-threatening diseases caused by Plasmodium protozoa transmitted by an infective female 
Anopheles mosquito vector. Treatment is influenced by the species causing the infection, including Plasmodium 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. Hence, it should be prevented through vector control 
using insecticide treated nets and genetically engineered mosquitoes. Vernonia amygdalina can be found in most 
of Ethiopian regions and used for the treatment of different alignments including malaria in rural communities. 
Therefore, the antimalarial activities the plant should be further investigated to be used for the treatment of malaria.  
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